Semaglutide mkt settles into steady growth six months after patent expiry | Industry News
Six months after semaglutide lost patent protection in India, generic brands account for about 74 per cent of…
Why Tirzepatide Continues to Outpace Semaglutide in India
Three months after the patent on semaglutide (the active ingredient in Novo Nordisk’s diabetes and weight-loss drugs like…
Why the weight-loss drugs battle will intensify in 2026, explained in 5 charts
Novo executives project that oral pills could capture more than a third of the total obesity drug market…